LONDON, Sept. 2, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

The Elder Care Market: Products and Services



https://www.reportbuyer.com/product/128583/The-Elder-Care-Market-Products-and-Services.html

STUDY GOALS AND OBJECTIVES



The aim of this report is to provide an in-depth analysis and forecast of the pharmaceutical, housing and assistive device segments of the U.S. eldercare market. The report will focus on the size of the U.S. market, with comparisons to other markets in developed countries in Europe and Asia.

Demographic implications, funding implications for both individuals and countries, products and services currently available in the housing and assistive device markets, and research regarding future pharmaceutical treatments will be discussed. Future pharmaceutical treatments will concentrate on the areas of concern for individuals who are older than 65, including:

• Heart disease/stroke.

• Cancer treatments.

• Kidney disease medications

• Diabetes medications.

• Arthritis prescription medications.

• Osteoporosis medications.

• Pain medications.

• Neurological health medications (e.g., dementia, depression).

• Respiratory medications and products.

REASONS FOR DOING THE STUDY



Individuals born between 1946 and 1964 (commonly referred to as baby boomers) will have a profound effect on the structure of societies as well as the services and products offered by governments and manufacturers. This huge market of active, relatively wealthy and demanding individuals will place enormous stress on governments to provide services and on businesses to provide appropriate products. Outlining the impact of this generation and investigating current and future products and opportunities for well-positioned companies are the primary focuses of this report.

SCOPE OF REPORT



This report offers forecasts by product segment (i.e., pharmaceuticals, housing and assistive devices, and technology) from 2013 through 2018, including supporting analyses for projections.

Report segments include a demographic background of the market in the U.S. and worldwide, healthcare products and services, housing services and needs, and assistive technologies for the eldercare market. International markets are discussed and information is provided on industry structure.

Profiles of leading companies involved in the eldercare pharmaceutical, housing and assistive device industries are provided. Information on company placement within the designated market and strategic analyses of the company's available and emerging products is discussed.

INTENDED AUDIENCE



This report provides a broad background on the structure of the U.S. eldercare healthcare market and the chief issues it faces. It offers the information needed to understand the current market and to address the emerging one. Comparisons with the eldercare market in Europe, Asia and developing countries are provided.

This is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, investor consultants and others interested in the eldercare market, its products, participants and future.



INFORMATION SOURCES



Information for this report was obtained from industry participants; the Center for Medicare and Medicaid Services (CMS), National Institutes of Health (NIH), National Institutes on Aging, Agency on Health Care Policy and Research, the Centers for Disease Control (CDC), U.S. Census Bureau and other U.S. government agencies; The World Health Organization (WHO); the American Hospital Association, Alzheimer's Association, American Heart Association; The Gerontological Society of America, American Lung Association, American Medical Association, American Association of Retired Persons, Assisted Living Federation of America (ALFA); the Pew Charitable Trusts, Kaiser Family Foundation; Robert Wood Johnson Foundation and MetLife Mature Markets; industry experts; literature searches; company annual reports and 10Ks; and product literature.

All data collected were analyzed by BCC Research personnel to determine specific findings and to project markets. When precise information is not available, a consensus was made using reasonable assumptions and estimates based on historical data.

ANALYST CREDENTIALS



Peggy S. Lehr is the market research analyst of this report. Ms. Lehr holds a BS in Journalism from the University of Colorado, Boulder, and a MS in Communication from the University of Denver. Ms. Lehr has been involved with the medical/nursing industry for more than 25 years. Recent reports for BCC Research include nine healthcare reports and her latest report, HLC078B: Magnetic Resonance Imaging: The Global Market, which was published in September 2013.



REPORT HIGHLIGHTS



The U.S. eldercare market reached $286.7 billion in 2012. This market is expected to grow from $319.8 billion in 2013 to $436.6 billion by 2018, with a compound annual growth rate (CAGR) of 6.4% for the five-year period, 2013 to 2018.

This report provides:

• An in-depth analysis and forecast of the eldercare market.

• Analyses of market trends, with data from 2012, estimates for 2013, and projections of CAGRs for the period 2013 and 2018.

• Identification of the U.S. and worldwide markets by demographics.

• Discussion on international markets, as well as information on the industry's structure.

• A breakdown of the overall market into segments that include healthcare products and services, housing services and needs, and assistive technologies.

TABLE OF CONTENTS



CHAPTER 1 INTRODUCTION 2



STUDY GOALS AND OBJECTIVES 2

REASONS FOR DOING THE STUDY 2

SCOPE OF REPORT 2

INTENDED AUDIENCE 3

INFORMATION SOURCES 3

ANALYST CREDENTIALS 3

RELATED BCC RESEARCH REPORTS 4

BCC RESEARCH ONLINE SERVICES 4

DISCLAIMER 4



CHAPTER 2 SUMMARY 6



EMPHASIS OF THE REPORT 6

HEALTHCARE 6

HOUSING 7

ASSISTIVE TECHNOLOGY 7

SUMMARY TABLE PROJECTED NEEDS OF THE U.S. ELDERLY, THROUGH 2018 ($

MILLIONS) 8

SUMMARY FIGURE PROJECTED NEEDS OF THE ELDERLY BY TYPE OF NEED, 2013

AND 2018 (%) 9

CHAPTER 3 OVERVIEW OF GLOBAL ELDERLY POPULATION 11



DEFINITIONS 11

TRENDS IN GLOBAL AGING 11

HEALTHCARE AND AGING 11

HOUSING AND AGING 12

THE GLOBAL ENVIRONMENT FOR THE ELDERLY 12

GLOBAL SOCIAL ENVIRONMENT 12

Intergenerational Living Issues in Developing Countries 13

Intergenerational Living Issues in Developed Countries 13

GLOBAL HOUSING REALITY FOR THE ELDERLY 13

Europe 13

China 13

GLOBAL ECONOMIC REALITY FOR THE ELDERLY 14

Economic Trends for Elderly Outside the U.S. 14

Europe 14

India 14

Japan 15

Economic Trends for U.S. Elderly 15

GLOBAL DEMOGRAPHIC TRENDS, BY COUNTRY 15

TABLE 1 PERCENT OF POPULATION AGE 65 AND OLDER IN SELECTED COUNTRIES,

2012 (MILLIONS/%) 15

THE ELDERLY IN THE U.S. 16

DEMOGRAPHICS IN THE U.S. 16

TABLE 2 ELDERLY POPULATIONS COMPARED WITH OVERALL POPULATIONS BY

STATE, 2009 16

TABLE 3 U.S. ELDERLY POPULATION, BY STATE, AS A PERCENTAGE OF THE

OVERALL STATE POPULATION, 2010 (%) 18

HEALTH OF THE U.S. ELDERLY 19

U.S. Health Trends 19

Discrepancies in Minority Health Status 19

Elderly Living with Chronic Health Conditions 20

SHIFTING DEMOGRAPHICS IN THE U.S. 20

Racial and Ethnic Changes 20

FIGURE 1 U.S. POPULATION OVER 65 BY RACE, 2010 (%) 20

GOVERNMENT LEGISLATION AND PROGRAMS AIMED AT THE ELDERLY 21

THE AMERICANS WITH DISABILITIES ACT 21

ADA and Employee Rights 22

THE TELECOMMUNICATIONS ACT OF 1934 22

THE FAIR HOUSING ACT 22

AIR CARRIER ACCESS ACT 23

VOTING ACCESSIBILITY FOR THE ELDERLY AND HANDICAPPED ACT OF

1984 23

ARCHITECTURAL BARRIERS ACT OF 1968 23

MEDICAL DEVICE LEGISLATION 23

THE AMERICAN RECOVERY AND REINVESTMENT ACT OF 2009 24

U.S. GOVERNMENT SPONSORED NUTRITION PROGRAMS 24

NON-GOVERNMENTAL NUTRITION PROGRAMS 24

END-OF-LIFE CONSIDERATIONS 25

LEGAL MATTERS 25

CHAPTER 4 INDUSTRY TRENDS BY SECTOR-HEALTHCARE 27



U.S. HEALTHCARE FOR THE ELDERLY 27

TABLE 4 PROJECTED U.S. MARKET FOR ELDERCARE HEALTHCARE MEDICATIONS,

PRODUCTS AND SURGICAL PROCEDURES, THROUGH 2018 ($ MILLIONS) 28

HOSPITALIZATIONS FOR HEALTHCARE PROBLEMS OF THE ELDERLY 28

TABLE 5 NUMBER OF DISCHARGES FROM NONFEDERAL U.S. HOSPITALS FOR

INDIVIDUALS 65 OR OLDER, 2010 (THOUSANDS) 28

ARTHRITIS 29

CURRENT TREATMENTS 29

Medications 29

Rheumatoid Arthritis 30

COX2 Inhibitor 30

Disease-modifying Antirheumatic Drugs 30

Biologics to Treat RA 30

Corticosteroids 31

NSAIDs 31

Osteoarthritis 31

THE FUTURE BURDEN OF ARTHRITIS IN THE U.S. 31

FIGURE 2 FUTURE BURDEN OF ARTHRITIS FOR THOSE OVER 65 IN THE U.S. BY

GENDER, 2010-2030 ($ MILLIONS) 31

ARTHRITIS TREATMENT MARKET PROJECTIONS 32

TABLE 6 PROJECTED U.S. MARKET FOR PRESCRIPTION ARTHRITIS MEDICATIONS

FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 33

CARDIOVASCULAR DISEASES 33

CARDIOVASCULAR DISEASE IN THE U.S. 33

Risk Factors 34

Current Treatments for Heart Disease 34

TABLE 7 SELECTED LISTING OF HEART DISEASE MEDICATIONS BY BRAND NAME

AND MANUFACTURER 35

Surgical Options 37

CARDIOVASCULAR TREATMENT MARKET ANALYSIS 37

TABLE 8 U.S. MARKET FOR CARDIOVASCULAR DISEASE MEDICATIONS AND

SURGERY, THROUGH 2018 ($ MILLIONS) 38

TABLE 9 PROJECTED U.S. MARKET FOR CARDIOVASCULAR DRUGS AND SURGERY

FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 38

CANCER 38

TYPES OF CANCER 39

GLOBAL RISK FACTORS 39

FIGURE 3 ESTIMATED NEW CASES OF CANCER, GLOBALLY, 2008 (%) 39

CANCER RATES IN THE U.S. ELDERLY 40

CANCER TREATMENT MARKET ANALYSIS 41

TABLE 10 LEADING CANCER DRUGS, WITH PRODUCT, MANUFACTURER AND

INDICATION, 2012 41

MARKET ANALYSIS FOR U.S. CANCER DRUGS 42

TABLE 11 PROJECTED U.S. MARKET FOR CANCER TREATMENT DRUGS, THROUGH

2018 ($ MILLIONS) 42

TABLE 12 PROJECTED MARKET FOR CANCER DRUGS FOR U.S. ELDERLY PATIENTS,

THROUGH 2018 ($ MILLIONS) 42

DIABETES 43

TYPE 2 DIABETES INTERNATIONALLY 43

Type 2 Diabetes in Asia 43

PREVALENCE OF TYPE 2 DIABETES IN THE U.S. 44

TABLE 13 PREVALENCE OF DIABETES IN THE U.S., THROUGH 2018 (CASES IN

MILLIONS) 44

CURRENT TREATMENT OF DIABETES 44

TYPE 1 DIABETES 44

Insulin 44

Insulin Administration Devices 45

TYPE 2 DIABETES 45

Sulfonylureas 45

TABLE 14 SULFONYLUREAS 46

Biguanides 46

Alpha-Glucosidase Inhibitor 46

Glitazones 47

Prandial Glucose Regulators 47

GLP-1 Analogs/Incretin Mimetics 47

Amylin Mimetic 47

TABLE 15 ORAL HYPOGYCEMICS 48

MONITORING DEVICES FOR DIABETES 48

DIABETES THERAPY MARKET LEADERS 49

DIABETES MARKET ANALYSIS 49

TABLE 16 PROJECTED U.S. MARKET FOR ORAL DIABETES MEDICATIONS AND

MONITORING PRODUCTS, THROUGH 2018 ($ MILLIONS) 49

TABLE 17 PROJECTED U.S. MARKET FOR ORAL DIABETES MEDICATIONS AND

MONITORING PRODUCTS FOR THE ELDERLY, THROUGH 2018 ($ MILLIONS) 50

SENSORY IMPAIRMENTS 50

TABLE 18 PROJECTED U.S. MARKET FOR SENSORY IMPAIRMENT PHARMACEUTICALS,

SURGERY AND PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2018 ($

MILLIONS)

50

SPEECH IMPAIRMENT 51

WRITING DIFFICULTY 51

VISION IMPAIRMENT 51

TABLE 19 ESTIMATED NUMBER OF CASES BY VISION PROBLEM FOR INDIVIDUALS

OVER 40, 2010 52

Macular Degeneration 52

TABLE 20 PROJECTED GLOBAL MARKET FOR PRODUCTS TO TREAT AMD, THROUGH

2018 ($ MILLIONS) 53

TABLE 21 PROJECTED U.S. MARKET FOR PRODUCTS TO TREAT AMD FOR

INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 53

Cataracts 53

TABLE 22 PROJECTED COSTS OF CATARACT SURGERY FOR THE U.S. ELDERLY,

THROUGH 2018 ($ MILLIONS) 54

Glaucoma 54

Ethnic Disparities 54

Glaucoma Prescription Market 55

TABLE 23 PROJECTED U.S. ELDERLY MARKET FOR GLAUCOMA PRESCRIPTION

MEDICATIONS, THROUGH 2018 ($ MILLIONS) 55

Eyewear 55

TABLE 24 PROJECTED U.S. EYEWEAR SALES, THROUGH 2018 ($ MILLIONS) 56

Market for Eyewear Products for Seniors 56

TABLE 25 PROJECTED U.S. MARKET FOR EYEWEAR FOR INDIVIDUALS OVER 65,

THROUGH 2018 ($ MILLIONS) 56

HEARING IMPAIRMENT 57

Causes of Hearing Loss 57

Market Analysis for Hearing Aid Products 57

TABLE 26 PROJECTED U.S. MARKET FOR HEARING AID PRODUCTS, THROUGH 2018

($ MILLIONS) 58

TABLE 27 PROJECTED U.S. MARKET FOR HEARING AID PRODUCTS FOR THE

ELDERLY, THROUGH 2018 ($ MILLIONS) 58

NEUROLOGICAL DISEASES 58

TABLE 28 PROJECTED MARKET IN THE U.S. FOR DEMENTIA AND DEPRESSION

MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 59

ALZHEIMER'S DISEASE 59

FIGURE 4 CAUSES OF DEMENTIA IN INDIVIDUALS OVER 65 (%) 60

Economic Burden 60

Current Treatments for Alzheimer's 61

TABLE 29 COMMON PRESCRIPTION MEDICATIONS FOR ALZHEIMER'S DISEASE,

2013 62

Market Analysis for Dementia Costs 62

TABLE 30 PROJECTED MARKET IN THE U.S. FOR DEMENTIA MEDICATIONS FOR

INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 63

DEPRESSION 63

Origins of the Disease 63

Genetic Factors 63

Biological Factors 64

Sociological Factors 64

Psychological Factors 64

Costs of Depression 64

Market Analysis for Depression in the Elderly 65

TABLE 31 PROJECTED U.S. MARKET FOR DEPRESSION MEDICATIONS FOR THE

ELDERLY, THROUGH 2018 ($ MILLIONS) 65

ORTHOPEDIC 65

TABLE 32 PROJECTED U.S. MARKET FOR ORTHOPEDIC MEDICATIONS AND

SURGERIES FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 66

OSTEOPOROSIS 66

TABLE 33 UNCONTROLLABLE AND CONTROLLABLE RISK FACTORS FOR

OSTEOPOROSIS 66

Osteoporosis Medications 67

TABLE 34 OSTEOPOROSIS MEDICATIONS BY TYPE 67

Market Analysis for Osteoporosis Medications 67

TABLE 35 PROJECTED U.S. MARKET FOR OSTEOPOROSIS MEDICATIONS, THROUGH

2018 ($ MILLIONS) 68

TABLE 36 PROJECTED U.S. MARKET FOR OSTEOPOROSIS MEDICATIONS FOR

INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 68

FALLS AND THE ELDERLY 68

JOINT REPLACEMENT 68

Market Analysis 69

TABLE 37 PROJECTED U.S. COST OF SELECTED ORTHOPEDIC SURGERY, THROUGH

2018 ($ MILLIONS) 69

TABLE 38 PROJECTED U.S. COST OF SELECTED ORTHOPEDIC SURGERY FOR

INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 70

Market Leaders 70

FIGURE 5 MARKET LEADERS FOR RECONSTRUCTIVE IMPLANT PRODUCTS (%) 70

RESPIRATORY 71

TABLE 39 PROJECTED U.S. MARKET FOR RESPIRATORY MEDICATIONS AND

PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 71

ALLERGIES 72

Current Treatments for Allergies 72

TABLE 40 CURRENT ALLERGY TREATMENTS 73

Allergy Market Analysis 74

TABLE 41 PROJECTED MARKET FOR PRESCRIPTION ALLERGY MEDICATIONS IN THE

U.S., THROUGH 2018 ($ MILLIONS) 74

TABLE 42 PROJECTED U.S. MARKET FOR PRESCRIPTION ALLERGY MEDICATIONS

FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 75

ASTHMA 75

Treatments 76

TABLE 43 PROJECTED U.S. MARKET FOR ASTHMA MEDICATIONS FOR INDIVIDUALS

OVER 65, THROUGH 2018 ($ MILLIONS) 76

COPD 76

TABLE 44 PROJECTED U.S. MARKET FOR COPD MEDICATIONS FOR INDIVIDUALS

OVER 65, THROUGH 2018 ($ MILLIONS) 77

COPD Treatment Options 77

TABLE 45 CURRENT TREATMENT OPTIONS FOR ASTHMA/COPD IN U.S. 78

Emphysema 79

Chronic Bronchitis 79

OXYGEN THERAPY 79

TABLE 46 PROJECTED U.S. MARKET FOR HOME OXYGEN AND RESPIRATORY

SUPPLIES FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 80

LOSS OF PATENT PROTECTION 80

TABLE 47 MAJOR ASTHMA/COPD DRUGS LOSING PATENT PROTECTION BETWEEN

2008–2021 80

OTHER CHRONIC CONDITIONS 81

DENTAL HEALTH 81

UROLOGICAL PROBLEMS 81

Incontinence Medications 81

TABLE 48 PROJECTED U.S. MARKET FOR INCONTINENCE MEDICATIONS FOR

INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 82

BENIGN PROSTATIC HYPERPLASIA (BPH) 82

TABLE 49 SELECTED MEDICATIONS FOR BPH 82

TABLE 50 PROJECTED U.S. MARKET FOR BPH MEDICATIONS FOR INDIVIDUALS

OVER 65, THROUGH 2018 ($ MILLIONS) 83

OBESITY 83

CHAPTER 5 INDUSTRY TRENDS BY SECTOR-HOUSING 85



UNPAID CAREGIVERS 85

TOLL ON CAREGIVERS 85

LONG-TERM CARE 86

FIGURE 6 PROJECTED LIFETIME LONG-TERM CARE NEEDS FOR INDIVIDUALS OVER

65 (%) 86

U.S. HOUSING FOR ELDERLY 87

MARKET ANALYSIS 87

TABLE 51 PROJECTED U.S. MARKET FOR SENIOR HOUSING AND DAY SERVICES FOR

INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 88

AT-HOME REMODELING 88

TABLE 52 PROJECTED U.S. MARKET FOR HOME REMODELING FOR INDIVIDUALS

OVER 65, THROUGH 2018 ($ MILLIONS) 89

HOME HEALTHCARE SERVICES 89

TABLE 53 PROJECTED U.S. MARKET FOR HOME HEALTH SERVICES FOR

INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 89

ADULT DAY CENTERS 90

TABLE 54 PROJECTED U.S. MARKET FOR ADULT DAY CARE SERVICES FOR

INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 91

COMPETITIVE LANDSCAPE FOR HOME HEALTHCARE SERVICES 91

HOUSING FOR LOWER INCOME INDIVIDUALS 91

INSTITUTIONAL CARE ALTERNATIVES FOR SENIORS 92

DEMOGRAPHICS OF INDIVIDUALS IN INSTITUTIONAL SETTINGS 92

ASSISTED LIVING, SKILLED NURSING, MEMORY CARE PROVIDERS 93

TABLE 55 PROJECTED U.S. MARKET FOR SENIOR ASSISTED LIVING AND SKILLED

NURSING FACILITIES FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 93

TOP INDUSTRY PROVIDERS 93

TABLE 56 TOP 10 ASSISTED LIVING PROVIDERS IN U.S. BY CAPACITY, 2012 94

FIGURE 7 PERCENT RANKING OF ASSISTED LIVING PROVIDERS BY CAPACITY IN THE

U.S., 2012 (%) 94

TABLE 57 TOP 10 INDEPENDENT LIVING PROVIDERS BY CAPACITY, 2012 95

FIGURE 8 PERCENT RANKING OF INDEPENDENT LIVING PROVIDERS BY CAPACITY IN

THE U.S., 2012 (%) 96

TABLE 58 TOP FIVE MEMORY CARE LIVING PROVIDERS IN THE U.S., 2012 97

ASSISTED LIVING 97

NURSING HOMES 97

MEMORY CARE 98

MARKET CONSTRAINTS 98

RESTRICTED SUPPLY OF NURSING BEDS 98

COST CONTAINMENT EFFORTS BY GOVERNMENT PAYERS 99

IMPLICATIONS OF THE AFFORDABLE CARE ACT (ACA) 99

Care Coordination 99

REIMBURSEMENT ISSUES 100

Medicaid Reimbursement 100

LACK OF FINANCIAL RESOURCES BY SENIORS 100

INDUSTRY COMPETITION 100

RETAINING COMPETENT STAFF 101

CREDIT AND MODERNIZATION FOR SKILLED NURSING FACILITIES 101

INDEPENDENT LIVING 101

ACTIVE ADULT COMMUNITIES 102

RECREATIONALLY BASED RETIREMENT COMMUNITIES 102

SENIOR HOUSING MARKET OPPORTUNITIES 103

MEMORY CARE FACILITIES 103

HOME HEALTHCARE 103

U.S. REGIONAL ANALYSIS 103

NEW FACILITY CONSTRUCTION 103

ACQUISITIONS AND MERGERS IN THE ELDERCARE HOUSING INDUSTRY 103

TABLE 59 SELECTED ACQUISITIONS AND MERGERS IN THE ELDERCARE MARKET,

2011 TO 2013 ($ MILLIONS) 104

CHAPTER 6 INDUSTRY TRENDS, BY SECTOR-ASSISTIVE TECHNOLOGIES 106



PROJECTED ASSISTIVE TECHNOLOGIES MARKET ANALYSIS FOR ELDERS 106

TABLE 60 PROJECTED U.S. ASSISTIVE TECHNOLOGY MARKET FOR INDIVIDUALS

OVER 65, THROUGH 2018 ($ MILLIONS) 106

FIGURE 9 PROJECTED U.S. MARKET FOR ASSISTIVE TECHNOLOGY FOR INDIVIDUALS

OVER 65, 2013 AND 2018 (%) 107

MEDICAL AND PERSONAL MONITORING AIDS 108

ACTIVITY LOCATION/PERSONAL MONITORING AIDS 108

Activity/Emergency Location Monitors 108

Remote Medical Monitors 108

Market Fragmentation 109

TABLE 61 SELECTED MEDICAL/PERSONAL MONITORING AID MANUFACTURERS 109

MEDICAL/PERSONAL MONITORING AIDS MARKET GROWTH 109

TABLE 62 PROJECTED U.S. SALES OF MEDICAL/PERSONAL MONITORING AIDS FOR

INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 110

MARKET DRIVERS FOR MEDICAL AND PERSONAL MONITORING AIDS 110

ACCESS AIDS 110

HOME ELEVATORS 110

WHEELCHAIR LIFTS 110

STAIR CLIMBERS 111

ACCESSIBLE BATHS AND SHOWERS 111

TRANSFER LIFTS 111

DOOR OPENERS 111

ACCESS AIDS MANUFACTURERS 111

TABLE 63 ACCESS AIDS MANUFACTURERS 112

DAILY LIVING AIDS 112

TABLE 64 SELECTED MANUFACTURERS OF DAILY LIVING AIDS 113

PROJECTED MARKET FOR DAILY LIVING AIDS FOR SENIORS 113

TABLE 65 PROJECTED MARKET FOR DAILY LIVING AIDS FOR SENIORS, THROUGH

2018 ($ MILLIONS) 113

MOBILITY AIDS 114

TABLE 66 PROJECTED U.S. MARKET FOR MOBILITY PRODUCTS FOR INDIVIDUALS

OVER 65, THROUGH 2018 ($ MILLIONS) 114

WHEELCHAIRS, SCOOTERS AND ACCESSORIES 114

Wheelchairs 114

TABLE 67 WHEELCHAIR MANUFACTURERS 115

Scooters 116

TABLE 68 SCOOTER MANUFACTURERS 116

AMBULATORY AIDS 116

TABLE 69 PROJECTED U.S. MARKET FOR AMBULATORY AIDS FOR INDIVIDUALS

OVER 65, THROUGH 2018 ($ MILLIONS) 117

TABLE 70 AMBULATORY AID MANUFACTURERS 117

MOTOR VEHICLE MODIFICATIONS 117

TABLE 71 PROJECTED U.S. MARKET FOR MOTOR VEHICLE MODIFICATIONS FOR

INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 118

TABLE 72 VEHICLE ASSESS CONVERSION KIT MANUFACTURERS 118

NAVIGATION AIDS 118

TABLE 73 PROJECTED U.S. MARKET FOR NAVIGATION AIDS FOR INDIVIDUALS OVER

65, THROUGH 2018 ($ MILLIONS) 119

OTHER AIDS 119

TABLE 74 PROJECTED U.S. MARKET FOR OTHER AIDS FOR INDIVIDUALS OVER 65,

THROUGH 2018 ($ MILLIONS) 119

BEDS 120

ERGONOMIC AIDS 120

COMMUNICATION AIDS 120

TABLE 75 PROJECTED U.S. ELDERLY MARKET FOR COMMUNICATION AIDS,

THROUGH 2018 ($ MILLIONS) 120

Speech Aids 121

Writing Aids/Computer Access 121

Input Devices 121

Output Devices 121

Software Products 121

Telephony Accessories 122

Text Telephones 122

Amplified Telephones 122

Vision/Reading Aids 122

CHAPTER 7 DEVELOPMENTAL PIPELINE FOR ELDERCARE PHARMACEUTICALS 124



TABLE 76 MEDICINES IN DEVELOPMENT FOR SELECTED THERAPEUTIC AREAS,

2012 124

CANCER 124

BREAST 124

TABLE 77 MAJOR PRODUCT PIPELINES FOR BREAST CANCER 125

COLORECTAL CANCER 125

TABLE 78 MAJOR PRODUCT PIPELINES FOR COLORECTAL CANCER 126

DIABETES 126

TABLE 79 MAJOR PRODUCT PIPELINES FOR DIABETES 126

HEART DISEASE/STROKE 128

TABLE 80 MAJOR PRODUCT PIPELINES FOR HEART DISEASE/STROKE 128

KIDNEY DISEASE 128

TABLE 81 MAJOR PRODUCT PIPELINES FOR KIDNEY DISEASE 128

MUSCULOSKELETAL 129

OSTEOARTHRITIS 129

TABLE 82 MAJOR PRODUCT PIPELINES FOR OSTEOARTHRITIS 129

OSTEOPOROSIS 129

TABLE 83 MAJOR PRODUCT PIPELINES FOR OSTEOPOROSIS 129

Pain 130

TABLE 84 MAJOR PRODUCT PIPELINES FOR PAIN 130

Rheumatoid Arthritis 130

TABLE 85 MAJOR PRODUCT PIPELINES FOR RHEUMATOID ARTHRITIS 131

NEUROLOGICAL 131

DEPRESSION PRODUCT PIPELINE 131

TABLE 86 MAJOR PRODUCT PIPELINES FOR DEPRESSION 132

DEMENTIA PRODUCT PIPELINE 132

TABLE 87 MAJOR PRODUCT PIPELINE FOR DEMENTIA PHARMACEUTICALS 133

RESPIRATORY 133

ASTHMA 133

TABLE 88 MAJOR PRODUCT PIPELINES FOR ASTHMA 133

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 134

TABLE 89 MAJOR PRODUCT PIPELINES FOR COPD 134

CHAPTER 8 COMPANY DIRECTORY 136



PHARMACEUTICALS 136

ABBOTT LABORATORIES 136

Business Overview 136

Products 136

ASTRAZENECA PLC 137

Business Overview 137

Products 137

BRISTOL-MYERS SQUIBB 137

Business Overview 137

Products 137

CENTOCOR 138

Business Overview 138

Products 138

COVIDIEN 138

Business Overview 138

Products 138

DJO GLOBAL, INC. 138

Business Overview 139

Products 139

ELI LILLY 139

Business Overview 139

Products 139

ENDO PHARMACEUTICALS, INC. 139

Business Overview 139

Products 140

FOREST PHARMACEUTICALS 140

Business Overview 140

Products 140

GLAXOSMITHKLINE PLC 140

Business Overview 140

Products 140

JANSSEN PHARMACEUTICALS, INC. 141

Business Overview 141

Products 141

JOHNSON & JOHNSON 141

Business Overview 141

Products 141

MERCK 142

Business Overview 142

Products 142

NOVARTIS INTERNATIONAL AG 142

Business Overview 142

Products 142

NOVO NORDISK 143

Business Overview 143

Products 143

PFIZER 143

Business Overview 143

Products 143

PURDUE PHARMACEUTICALS LP 144

Business Overview 144

Products 144

ROCHE PHARMACEUTICALS 144

Business Overview 144

Products 144

SANOFI-AVENTIS 145

Business Overview 145

Products 145

SERVIER LABORATORIES, LTD 145

Business Overview 145

Products 145

TAKEDA PHARMACUETICALS 146

Business Overview 146

Products 146

VECTURA GROUP PLC 146

Business Overview 146

MEDICAL DEVICES 146

BOSTON SCIENTIFIC 146

Business Overview 147

Products 147

MEDTRONIC, INC. 147

Business Overview 147

Products 147

ST. JUDE MEDICAL, INC. 147

Business Overview 148

Products 148

HOUSING OPTIONS 148

ASSISTED LIVING CONCEPTS, LLC 148

Business Overview 148

Products 148

BROOKDALE SENIOR LIVING 148

Business Overview 149

Products 149

CAPITAL SENIOR LIVING CORP. 149

Business Overview 149

Products 149

EMERITUS CORP. 149

Business Overview 150

Products 150

FIVE STAR QUALITY CARE, INC. 150

Business Overview 150

Products 150

LIFE CARE CENTERS OF AMERICA 150

Business Overview 150

Products 150

LIVHOME, INC. 151

Business Overview 151

Products 151

HCR MANOR CARE 151

Business Overview 151

Products 151

SUNRISE SENIOR LIVING, INC. 151

Business Overview 152

Products 152

ASSISTIVE DEVICES 152

A&D MEDICAL/LIFESOURCE 152

Business Overview 152

Products 152

ALIMED INC. 152

Business Overview 152

Products 153

ALLIED HEALTHCARE PRODUCTS, INC. 153

Business Overview 153

Products 153

AMERICAN MEDICAL ALERT CORP. 153

Business Overview 153

Products 153

ANALOGIC INC. 154

Business Overview 154

Products 154

BAXTER INTERNATIONAL, INC. 154

Business Overview 154

Products 154

BAYER AG (MILES-BAYER) 155

Business Overview 155

Products 155

BLUE CHIP MEDICAL PRODUCTS 155

Business Overview 155

Products 155

BRUNO INDEPENDENT LIVING AIDS INC. 155

Business Overview 156

Products 156

CARD GUARD AG 156

Business Overview 156

Products 156

CARETRENDS 156

Business Overview 156

Products 157

COBOLT SYSTEMS LTD. 157

Business Overview 157

Products 157

DOLPHIN COMPUTER ACCESS LTD. 157

Business Overview 157

Products 158

DUXBURY SYSTEMS INC. 158

Business Overview 158

Products 158

ECHO THERAPEUTICS 158

Business Overview 158

Products 158

EXACT DYNAMICS B.V. 159

Business Overview 159

Products 159

FREEDOM SCIENTIFIC INC. 159

Business Overview 159

Products 159

FRESENIUS MEDICAL CARE AG & CO. KGAA 160

Business Overview 160

Products 160

GRAHAM-FIELD HEALTH PRODUCTS 160

Business Overview 160

Products 160

GW MICRO INC. 160

Business Overview 161

Products 161

HEALTH FRONTIER, INC. 161

Business Overview 161

Products 161

HONEYWELL HOMMED 161

Business Overview 161

Products 162

HUMANWARE 162

Business Overview 162

Products 162

INCLINATOR COMPANY OF AMERICA 162

Business Overview 162

Products 162

INVACARE CORP. 163

Business Overview 163

Products 163

JOHNSON & JOHNSON 163

Business Overview 163

Products 163

KIMBERLY CLARK 163

Business Overview 164

Products 164

KROWN MANUFACTURING 164

Business Overview 164

Products 164

LIFE ALERT EMERGENCY RESPONSE 164

Business Overview 164

Products 164

LIFE GUARDIAN LLC 165

Business Overview 165

Products 165

LIFESCAN, INC. 165

Business Overview 165

Products 165

LIFTAVATOR INC. 165

Business Overview 166

Products 166

MEDLINE INDUSTRIES INC. 166

Business Overview 166

Products 166

MEDTRONIC MINIMED 166

Business Overview 166

Products 166

NIPRO DIAGNOSTICS INC. 167

Business Overview 167

Products 167

NXSTAGE MEDICAL, INC. 167

Business Overview 167

Products 167

OBS MEDICAL 167

Business Overview 168

Products 168

OMRON HEALTHCARE, INC. 168

Business Overview 168

Products 168

OPTELEC 168

Business Overview 169

Products 169

OTTO BOCK HEALTHCARE GMBH 169

Business Overview 169

Products 169

PARI PHARMA 169

Business Overview 169

Products 170

PHILIPS LIFELINE SYSTEMS INC. 170

Business Overview 170

Products 170

PRIDE MOBILITY PRODUCTS CORP. 170

Business Overview 170

Products 170

PULSE METRIC INC. 171

Business Overview 171

Products 171

RESMED, INC. 171

Business Overview 171

Products 171

ROCHE DIAGNOSTICS 171

Business Overview 172

Products 172

SAVARIA CORP. 172

Business Overview 172

Products 172

SCOTTCARE CORP. 172

Business Overview 172

Products 173

SIEMENS HEARING INSTRUMENTS INC. 173

Business Overview 173

Products 173

STARKEY LABORATORIES 173

Business Overview 173

Products 173

SUNRISE MEDICAL INC. 174

Business Overview 174

Products 174

SVENSKA CELLULOSA AKTIEBOLAGET SCA 174

Business Overview 174

Products 174

THORNDIKE PRESS 174

Business Overview 175

Products 175

THYSSENKRUPP ACCESS 175

Business Overview 175

Products 175

TYCO INTERNATIONAL 175

Business Overview 175

Products 175

WIDEX 176

Business Overview 176

Products 176

REHABILITATION 176

DJO GLOBAL, INC. 176

Business Overview 176

Products 176

KINDRED HEALTHCARE 177

Business Overview 177

Products 177

CHAPTER 9 GLOSSARY 179



ACTIVITIES OF DAILY LIVING (ADLS) 179

ALZHEIMER'S DISEASE 179

ARTHRITIS 179

ASSISTED LIVING 179

ASSISTIVE TECHNOLOGY 179

BABY BOOMER 180

CARDIOVASCULAR DISEASE 180

CAREGIVERS 180

CONGESTIVE OBSTRUCTIVE PULMONARY DISEASE (COPD) 180

DEMENTIA 180

DIABETES 180

DURABLE MEDICAL EQUIPMENT 181

ELDER/SENIOR 181

GERONTOLOGY 181

HOSPICE CARE 181

INSTRUMENTAL ACTIVITIES OF DAILY LIVING (IADL) 181

LONG-TERM CARE 181

PROSTHETICS AND ORTHOTICS 181

LIST OF TABLES



SUMMARY TABLE PROJECTED NEEDS OF THE U.S. ELDERLY, THROUGH 2018 ($

MILLIONS) 8

TABLE 1 PERCENT OF POPULATION AGE 65 AND OLDER IN SELECTED COUNTRIES,

2012 (MILLIONS/%) 15

TABLE 2 ELDERLY POPULATIONS COMPARED WITH OVERALL POPULATIONS BY

STATE, 2009 16

TABLE 3 U.S. ELDERLY POPULATION, BY STATE, AS A PERCENTAGE OF THE OVERALL

STATE POPULATION, 2010 (%) 18

TABLE 4 PROJECTED U.S. MARKET FOR ELDERCARE HEALTHCARE MEDICATIONS,

PRODUCTS AND SURGICAL PROCEDURES, THROUGH 2018 ($ MILLIONS) 28

TABLE 5 NUMBER OF DISCHARGES FROM NONFEDERAL U.S. HOSPITALS FOR

INDIVIDUALS 65 OR OLDER, 2010 (THOUSANDS) 28

TABLE 6 PROJECTED U.S. MARKET FOR PRESCRIPTION ARTHRITIS MEDICATIONS FOR

INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 33

TABLE 7 SELECTED LISTING OF HEART DISEASE MEDICATIONS BY BRAND NAME AND

MANUFACTURER 35

TABLE 8 U.S. MARKET FOR CARDIOVASCULAR DISEASE MEDICATIONS AND SURGERY,

THROUGH 2018 ($ MILLIONS) 38

TABLE 9 PROJECTED U.S. MARKET FOR CARDIOVASCULAR DRUGS AND SURGERY

FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 38

TABLE 10 LEADING CANCER DRUGS, WITH PRODUCT, MANUFACTURER AND

INDICATION, 2012 41

TABLE 11 PROJECTED U.S. MARKET FOR CANCER TREATMENT DRUGS, THROUGH

2018 ($ MILLIONS) 42

TABLE 12 PROJECTED MARKET FOR CANCER DRUGS FOR U.S. ELDERLY PATIENTS,

THROUGH 2018 ($ MILLIONS) 42

TABLE 13 PREVALENCE OF DIABETES IN THE U.S., THROUGH 2018 (CASES IN

MILLIONS) 44

TABLE 14 SULFONYLUREAS 46

TABLE 15 ORAL HYPOGYCEMICS 48

TABLE 16 PROJECTED U.S. MARKET FOR ORAL DIABETES MEDICATIONS AND

MONITORING PRODUCTS, THROUGH 2018 ($ MILLIONS) 49

TABLE 17 PROJECTED U.S. MARKET FOR ORAL DIABETES MEDICATIONS AND

MONITORING PRODUCTS FOR THE ELDERLY, THROUGH 2018 ($ MILLIONS) 50

TABLE 18 PROJECTED U.S. MARKET FOR SENSORY IMPAIRMENT PHARMACEUTICALS,

SURGERY AND PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 50

TABLE 19 ESTIMATED NUMBER OF CASES BY VISION PROBLEM FOR INDIVIDUALS

OVER 40, 2010 52

TABLE 20 PROJECTED GLOBAL MARKET FOR PRODUCTS TO TREAT AMD, THROUGH

2018 ($ MILLIONS) 53

TABLE 21 PROJECTED U.S. MARKET FOR PRODUCTS TO TREAT AMD FOR

INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 53

TABLE 22 PROJECTED COSTS OF CATARACT SURGERY FOR THE U.S. ELDERLY,

THROUGH 2018 ($ MILLIONS) 54

TABLE 23 PROJECTED U.S. ELDERLY MARKET FOR GLAUCOMA PRESCRIPTION

MEDICATIONS, THROUGH 2018 ($ MILLIONS) 55

TABLE 24 PROJECTED U.S. EYEWEAR SALES, THROUGH 2018 ($ MILLIONS) 56

TABLE 25 PROJECTED U.S. MARKET FOR EYEWEAR FOR INDIVIDUALS OVER 65,

THROUGH 2018 ($ MILLIONS) 56

TABLE 26 PROJECTED U.S. MARKET FOR HEARING AID PRODUCTS, THROUGH 2018

($ MILLIONS) 58

TABLE 27 PROJECTED U.S. MARKET FOR HEARING AID PRODUCTS FOR THE ELDERLY,

THROUGH 2018 ($ MILLIONS) 58

TABLE 28 PROJECTED MARKET IN THE U.S. FOR DEMENTIA AND DEPRESSION

MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 59

TABLE 29 COMMON PRESCRIPTION MEDICATIONS FOR ALZHEIMER'S DISEASE, 2013 62

TABLE 30 PROJECTED MARKET IN THE U.S. FOR DEMENTIA MEDICATIONS FOR

INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 63

TABLE 31 PROJECTED U.S. MARKET FOR DEPRESSION MEDICATIONS FOR THE

ELDERLY, THROUGH 2018 ($ MILLIONS) 65

TABLE 32 PROJECTED U.S. MARKET FOR ORTHOPEDIC MEDICATIONS AND

SURGERIES FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 66

TABLE 33 UNCONTROLLABLE AND CONTROLLABLE RISK FACTORS FOR

OSTEOPOROSIS 66

TABLE 34 OSTEOPOROSIS MEDICATIONS BY TYPE 67

TABLE 35 PROJECTED U.S. MARKET FOR OSTEOPOROSIS MEDICATIONS, THROUGH

2018 ($ MILLIONS) 68

TABLE 36 PROJECTED U.S. MARKET FOR OSTEOPOROSIS MEDICATIONS FOR

INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 68

TABLE 37 PROJECTED U.S. COST OF SELECTED ORTHOPEDIC SURGERY, THROUGH

2018 ($ MILLIONS) 69

TABLE 38 PROJECTED U.S. COST OF SELECTED ORTHOPEDIC SURGERY FOR

INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 70

TABLE 39 PROJECTED U.S. MARKET FOR RESPIRATORY MEDICATIONS AND

PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 71

TABLE 40 CURRENT ALLERGY TREATMENTS 73

TABLE 41 PROJECTED MARKET FOR PRESCRIPTION ALLERGY MEDICATIONS IN THE

U.S., THROUGH 2018 ($ MILLIONS) 74

TABLE 42 PROJECTED U.S. MARKET FOR PRESCRIPTION ALLERGY MEDICATIONS FOR

INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 75

TABLE 43 PROJECTED U.S. MARKET FOR ASTHMA MEDICATIONS FOR INDIVIDUALS

OVER 65, THROUGH 2018 ($ MILLIONS) 76

TABLE 44 PROJECTED U.S. MARKET FOR COPD MEDICATIONS FOR INDIVIDUALS

OVER 65, THROUGH 2018 ($ MILLIONS) 77

TABLE 45 CURRENT TREATMENT OPTIONS FOR ASTHMA/COPD IN U.S. 78

TABLE 46 PROJECTED U.S. MARKET FOR HOME OXYGEN AND RESPIRATORY

SUPPLIES FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 80

TABLE 47 MAJOR ASTHMA/COPD DRUGS LOSING PATENT PROTECTION BETWEEN

2008–2021 80

TABLE 48 PROJECTED U.S. MARKET FOR INCONTINENCE MEDICATIONS FOR

INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 82

TABLE 49 SELECTED MEDICATIONS FOR BPH 82

TABLE 50 PROJECTED U.S. MARKET FOR BPH MEDICATIONS FOR INDIVIDUALS OVER

65, THROUGH 2018 ($ MILLIONS) 83

TABLE 51 PROJECTED U.S. MARKET FOR SENIOR HOUSING AND DAY SERVICES FOR

INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 88

TABLE 52 PROJECTED U.S. MARKET FOR HOME REMODELING FOR INDIVIDUALS

OVER 65, THROUGH 2018 ($ MILLIONS) 89

TABLE 53 PROJECTED U.S. MARKET FOR HOME HEALTH SERVICES FOR INDIVIDUALS

OVER 65, THROUGH 2018 ($ MILLIONS) 89

TABLE 54 PROJECTED U.S. MARKET FOR ADULT DAY CARE SERVICES FOR

INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 91

TABLE 55 PROJECTED U.S. MARKET FOR SENIOR ASSISTED LIVING AND SKILLED

NURSING FACILITIES FOR INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 93

TABLE 56 TOP 10 ASSISTED LIVING PROVIDERS IN U.S. BY CAPACITY, 2012 94

TABLE 57 TOP 10 INDEPENDENT LIVING PROVIDERS BY CAPACITY, 2012 95

TABLE 58 TOP FIVE MEMORY CARE LIVING PROVIDERS IN THE U.S., 2012 97

TABLE 59 SELECTED ACQUISITIONS AND MERGERS IN THE ELDERCARE MARKET,

2011 TO 2013 ($ MILLIONS) 104

TABLE 60 PROJECTED U.S. ASSISTIVE TECHNOLOGY MARKET FOR INDIVIDUALS

OVER 65, THROUGH 2018 ($ MILLIONS) 106

TABLE 61 SELECTED MEDICAL/PERSONAL MONITORING AID MANUFACTURERS 109

TABLE 62 PROJECTED U.S. SALES OF MEDICAL/PERSONAL MONITORING AIDS FOR

INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 110

TABLE 63 ACCESS AIDS MANUFACTURERS 112

TABLE 64 SELECTED MANUFACTURERS OF DAILY LIVING AIDS 113

TABLE 65 PROJECTED MARKET FOR DAILY LIVING AIDS FOR SENIORS, THROUGH

2018 ($ MILLIONS) 113

TABLE 66 PROJECTED U.S. MARKET FOR MOBILITY PRODUCTS FOR INDIVIDUALS

OVER 65, THROUGH 2018 ($ MILLIONS) 114

TABLE 67 WHEELCHAIR MANUFACTURERS 115

TABLE 68 SCOOTER MANUFACTURERS 116

TABLE 69 PROJECTED U.S. MARKET FOR AMBULATORY AIDS FOR INDIVIDUALS OVER

65, THROUGH 2018 ($ MILLIONS) 117

TABLE 70 AMBULATORY AID MANUFACTURERS 117

TABLE 71 PROJECTED U.S. MARKET FOR MOTOR VEHICLE MODIFICATIONS FOR

INDIVIDUALS OVER 65, THROUGH 2018 ($ MILLIONS) 118

TABLE 72 VEHICLE ASSESS CONVERSION KIT MANUFACTURERS 118

TABLE 73 PROJECTED U.S. MARKET FOR NAVIGATION AIDS FOR INDIVIDUALS OVER

65, THROUGH 2018 ($ MILLIONS) 119

TABLE 74 PROJECTED U.S. MARKET FOR OTHER AIDS FOR INDIVIDUALS OVER 65,

THROUGH 2018 ($ MILLIONS) 119

TABLE 75 PROJECTED U.S. ELDERLY MARKET FOR COMMUNICATION AIDS, THROUGH

2018 ($ MILLIONS) 120

TABLE 76 MEDICINES IN DEVELOPMENT FOR SELECTED THERAPEUTIC AREAS, 2012 124

TABLE 77 MAJOR PRODUCT PIPELINES FOR BREAST CANCER 125

TABLE 78 MAJOR PRODUCT PIPELINES FOR COLORECTAL CANCER 126

TABLE 79 MAJOR PRODUCT PIPELINES FOR DIABETES 126

TABLE 80 MAJOR PRODUCT PIPELINES FOR HEART DISEASE/STROKE 128

TABLE 81 MAJOR PRODUCT PIPELINES FOR KIDNEY DISEASE 128

TABLE 82 MAJOR PRODUCT PIPELINES FOR OSTEOARTHRITIS 129

TABLE 83 MAJOR PRODUCT PIPELINES FOR OSTEOPOROSIS 129

TABLE 84 MAJOR PRODUCT PIPELINES FOR PAIN 130

TABLE 85 MAJOR PRODUCT PIPELINES FOR RHEUMATOID ARTHRITIS 131

TABLE 86 MAJOR PRODUCT PIPELINES FOR DEPRESSION 132

TABLE 87 MAJOR PRODUCT PIPELINE FOR DEMENTIA PHARMACEUTICALS 133

TABLE 88 MAJOR PRODUCT PIPELINES FOR ASTHMA 133

TABLE 89 MAJOR PRODUCT PIPELINES FOR COPD 134

LIST OF FIGURES



SUMMARY FIGURE PROJECTED NEEDS OF THE ELDERLY BY TYPE OF NEED, 2013

AND 2018 (%) 9

FIGURE 1 U.S. POPULATION OVER 65 BY RACE, 2010 (%) 20

FIGURE 2 FUTURE BURDEN OF ARTHRITIS FOR THOSE OVER 65 IN THE U.S. BY

GENDER, 2010-2030 ($ MILLIONS) 31

FIGURE 3 ESTIMATED NEW CASES OF CANCER, GLOBALLY, 2008 (%) 39

FIGURE 4 CAUSES OF DEMENTIA IN INDIVIDUALS OVER 65 (%) 60

FIGURE 5 MARKET LEADERS FOR RECONSTRUCTIVE IMPLANT PRODUCTS (%) 70

FIGURE 6 PROJECTED LIFETIME LONG-TERM CARE NEEDS FOR INDIVIDUALS OVER 65

(%) 86

FIGURE 7 PERCENT RANKING OF ASSISTED LIVING PROVIDERS BY CAPACITY IN THE

U.S., 2012 (%) 94

FIGURE 8 PERCENT RANKING OF INDEPENDENT LIVING PROVIDERS BY CAPACITY IN

THE U.S., 2012 (%) 96

FIGURE 9 PROJECTED U.S. MARKET FOR ASSISTIVE TECHNOLOGY FOR INDIVIDUALS

OVER 65, 2013 AND 2018 (%) 107

Read the full report:

The Elder Care Market: Products and Services



https://www.reportbuyer.com/product/128583/The-Elder-Care-Market-Products-and-Services.html

For more information:

Sarah Smith

Research Advisor at Reportbuyer.com

Email: query@reportbuyer.com

Tel: +44 208 816 85 48

Website: www.reportbuyer.com

SOURCE ReportBuyer